| name changed to RTL Corporation Limited | 23/05/2008 |
| securities reinstated to quotation | 19/05/2008 |
| the Company has now satisfied all pre-conditions to seeking reinstatement to trading of its securities on the Australian Securities Exchange and will be reinstated to quotation on Monday 19 May | 16/05/2008 |
| all resolutions were carried at the Company's General Meeting today | 16/04/2008 |
| capital of the company is being consolidated one share for every two held | 16/04/2008 |
| releases a placement prospectus | 25/03/2008 |
| releases half yearly accounts | 29/02/2008 |
| directors advise the market of certain material events that have allegedly resulted in the Company incurring substantial debts that the Directors were not previously aware of - as a result of these debts being brought to the attention of the Company, the Directors have limited options available to them to ensure that the Company remains a going concern | 22/02/2008 |
| a cash flow report for the quarter to 31 December 2007 shows a deficit at operating level of $70k and cash on hand of -$1k | 31/01/2008 |
| the company has recently begun discussions with another British company regarding the rights to the syringe technology - the company has several options for recapitalizing and moving forward, however these options are still in the process of being evaluated | 25/01/2008 |
| both resolutions at today's AGM were passed | 30/11/2007 |
| a cash flow report for the quarter to 30 September 2007 shows a deficit at operating level of $18k and cash on hand of $30k | 01/11/2007 |
| company provides notice of an Annual General Meeting to be held on Thursday 29 November 2007, at 11am (EST) at Level 12, 459 Collins Street, Melbourne, Victoria | 30/10/2007 |
| company releases its Preliminary Final Report | 31/08/2007 |
| company says its restructuring plan has been completed and overheads reduced to a minimum - the ASX trading halt on Ritract shares will stay in place until such time as the company has solid news to announce regarding three licensing deals | 28/08/2007 |
| a cash flow report for the quarter to 30 June 2007 shows a deficit at operating level of $146k and cash on hand of $48k | 31/07/2007 |
| after a restructuring, the company has only one employee, Mr Tom Davenport, who has been appointed Chief Executive Officer of the company (previously Head of Research and Development and Engineering) - the company is continuing discussions with companies who have expressed an interest in licensing the company's technology and/or have an interest in investing in the company | 30/07/2007 |
| MD Bill Nicklin and non-exec director Tony Fitzgerald resign | 29/06/2007 |
| securities suspended from quotation whilst a restructure is implemented | 26/06/2007 |
| shares reinstated to quotation | 08/11/2006 |
| company advises that pre market release testing found that a small percentage of products failed to operate correctly and under the rules of the QMS it is unable to release product - this had implications for the Company's ongoing funding requirements and in particular for the completion of its announced capital raising - it also prevented the completion and lodgement of Ritract's 2006 Annual Report - the Board has made the decision not to invest further funds into development of the Needlesleeve technology - the board expects the minor production issues to be overcome shortly | 16/10/2006 |
| securities suspended from quotation because of failure to lodge full year accounts for the period to 30 June 2006 | 02/10/2006 |
loading...
